Renal Endorsement Maintenance Steering Committee August 16-17, 2011

Marriott Metro Center 775 12th Street, NW Washington, DC 202-737-2200 800-393-2510

AGENDA

<u>Day 1 – August 16</u>

9:00 am	Welcome
	Peter Crooks, MD (Co-Chair) Helen Burstin, MD, MPH Senior Vice President of Performance Measures
	Karen Pace, PhD, RN, Senior Program Director
	Lauren Richie, MA, Project Manager
	Committee Introductions and Disclosures of Interest Ann Hammersmith, General Counsel
9:30 am	Project Overview and Evaluation Process
	Dr. Pace
	Ms. Richie
10:00 am	Consideration of Candidate Measures
	Anemia
	• 0252 Assessment of Iron Stores
	• 1660 ESRD Patients Receiving Dialysis: Hemoglobin Level <10g/dL
11:00 am	Break
11:15 am	(Anemia cont'd)
	• 1666 Patients on Erythropoiesis Stimulating Agent (ESA)Hgb Level > or = 12g/dL
	• 1667(Pediatric) ESRD Patients Receiving Dialysis: Hgb Level < 10g/dL
12:20 pm	NQF Member/Public Comment
12:30 pm	Lunch break
1:00 pm	Consideration of Candidate Measures
	Cardiovascular
	0626 Chronic Kidney Disease – Lipid Profile Monitoring

- 0627 Chronic Kidney Disease with LDL Greater than or equal to 130 Use of Lipid Lowering Agent
- **1668** Laboratory Testing (Lipid Profile)
- **1633** Blood Pressure Management
- **1662** Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy
- 2:30 pm Break

2:45 pm Consideration of Candidate Measures

Dialysis Adequacy

- 0249 Hemodialysis Adequacy Clinical Performance Measure III: Hemodialysis Adequacy--HD Adequacy-- Minimum Delivered Hemodialysis Dose
- 0250 Hemodialysis Adequacy Clinical Performance Measure III: Hemodialysis Adequacy-- HD Adequacy CPM III: Minimum Delivered Hemodialysis Dose
- 0323 Hemodialysis Adequacy: Solute
- 0247 Hemodialysis Adequacy Clinical Performance Measure I: Hemodialysis Adequacy- Monthly measurement of delivered dose
- 0248 Hemodialysis Adequacy Clinical Performance Measure II: Method of Measurement of Delivered Hemodialysis Dose
- 0318 Peritoneal Dialysis Adequacy- Delivered Dose of peritoneal dialysis above minimum
- 0321 Peritoneal Dialysis Adequacy: Solute
- 0253 Peritoneal Dialysis Adequacy- Measurement of total Solute Clearance at regular intervals
- **0254** Peritoneal Dialysis Adequacy- Calculate Weekly KT/Vurea in the Standard Way
- 4:50 pm NQF Member/Public Comment
- 5:00 pm Adjourn

<u>Day 2 – August 17</u>

- 8:00 am Welcome, Recap of Day One *Dr. Crooks*
- 8:15 am Consideration of Candidate Measures Mortality
 - 0369 Dialysis Facility Risk-adjusted Standardized Mortality Ratio (32) Level

Mineral Metabolism

- 0255 Measurement of Serum Phosphorus Concentration
- 0570 Chronic Kidney Disease (CKD): Monitoring Phosphorus

- 0261 Measurement of Serum Calcium Concentration
- 0574 Chronic Kidney Disease (CKD): Monitoring Calcium

10:00 am Break

10:15 am (Mineral Metabolism cont'd)

- **0571** Chronic Kidney Disease (CKD): Monitoring Parathyroid Hormone (PTH)
- **1655** ESRD patients with PTH >400pg/mL and not treated with a calcimimetic or vitamin D analog
- **1658** ESRD patients with PTH <130pg/mL and continued treatment with a calcimimetic or vitamin D analog

Consideration of Candidate Measures

Patient Education+ QoL

- 0320 Patient Education Awareness—Physician Level
- 0324 Patient Education Awareness—Facility Level
- 0260 Assessment of Health-related Quality of Life in Dialysis Patients

11:50 pm NQF Member/Public Comment

12:00 pm Lunch break

12:30 pm Consideration of Candidate Measures Vascular Access

- **0256** Hemodialysis Vascular Access- Minimizing use of catheters as Chronic Dialysis Access
- **0262** Vascular Access—Catheter Vascular Access and Evaluation by Vascular Surgeon for Permanent Access
- **0257** Hemodialysis Vascular Access- Maximizing Placement of Arterial Venous Fistula (AVF)
- **0251** Vascular Access—Functional AVF or Evaluation by Vascular Surgeon for Placement
- 0259 Hemodialysis Vascular Access Decision-making by Surgeon to Maximize Placement of Autogenous Arterial Venous Fistula

1:45 pm Break

- 2:00 pm Related and Competing Measures Measure Harmonization/Selection of Best Measure from Among Competing Measures
- 2:30 pm Recommendations for Measure Development
- 2:50 pm NQF Member/Public Comment

- 3:00 pm Next Steps/Timeline for Project
- 3:15 pm Adjourn